Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalAIDS Patient Care and STDs
Volume33
Issue number12
Pages (from-to)500-506
Number of pages7
ISSN1087-2914
DOIs
Publication statusPublished - Dec 2019
MoE publication typeA1 Journal article-refereed

Fields of Science

  • HIV
  • tenofovir disoproxil fumarate
  • tenofovir alafenamide
  • dyslipidemia
  • cholesterol
  • lipid-lowering effect
  • STATIN THERAPY
  • DOUBLE-BLIND
  • MYOCARDIAL-INFARCTION
  • LDL CHOLESTEROL
  • ADVERSE EVENTS
  • EZETIMIBE
  • EFFICACY
  • RISK
  • SAFETY
  • 3142 Public health care science, environmental and occupational health
  • 3121 Internal medicine

Cite this